Sensei Biotherapeutics, Inc. (SNSE) shares fell 33.29 percent to $11.73, down $5.85 on Friday after reporting results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA. The data were presented at the ESMO Congress 2025.
The stock traded between $10.52 and $17.50 during the session, compared with a previous close of $17.58 on the Nasdaq. Volume reached 744,100 shares, well above the average of 18,937.
The 52-week range is between $5.00 and $18.35.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.